When Every Sample Is A Life Trusted To Our Care: How CRL Automated Their Assay And Scale Throughput

Faced with the onset of the COVID-19 pandemic in the US in February 2020, Clinical Reference Labs (CRL) realized that they had the resources and capabilities to make a difference, and set out to develop a qPCR-based SARS-CoV-2 assay that could use self-collected samples.

In just a few months, they identified saliva as their desired sample type, developed an assay, and obtained Emergency Use Authorization from the FDA.

Discover how Artel® technology played a critical role in Clinical Reference Labs' exceptionally fast development and scale-up of a saliva-based SARS-CoV-2 assay to meet the unprecedented testing need.